As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Fulton Financial Corporation ("Fulton") today announced that it will distribute its first quarter 2025 earnings release and accompanying charts on Tuesday, April 15, at approximately 4:30 p.m. Eastern ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

The regulatory body concluded that the shortage of tirzepatide medicines is now resolved. However, NVO’s semaglutide is still ... as seen in the chart below. The stupendous success of Mounjaro ...

Ozempic and Wegovy, the first big names in this new era, used a GLP-1RA known as semaglutide ... another weight loss drug using tirzepatide (a GLP-1 like formulation) is no longer in short ...

Then I will share how we are leveraging the RaniPill technology to develop the next generation of obesity therapies, including our RT114 and semaglutide ... compared to tirzepatide and DAPIglutide ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.